Free tool · no signup
GLP-1 weight-loss projection
Curious what the clinical-trial averages look like on your scale? Enter your weight and pick a medication to apply the STEP and SURMOUNT trial averages — an illustration, not a prediction.
GLPMate charts your actual weight trend against your dose — so you can see your response, plateaus and all.
At the 19.5% average from SURMOUNT-1, a 90 kg start would reach about 72.4 kg — a loss of about 17.6 kg. Your result will differ.
Averages are mean total body-weight change with lifestyle support, at the trial endpoint. They are not a personal forecast.
Where these averages come from
The percentages are the mean weight change reported in the pivotal randomized trials — applied to your weight only to make the numbers relatable. They describe trial populations, not individuals.
| Medication | Trial | Avg. weight change | Duration |
|---|---|---|---|
| Wegovy 2.4 mg semaglutide | STEP 1 (NEJM 2021) | −14.9% | 68 wks |
| Zepbound 5 mg tirzepatide | SURMOUNT-1 (NEJM 2022) | −15% | 72 wks |
| Zepbound 10 mg tirzepatide | SURMOUNT-1 (NEJM 2022) | −19.5% | 72 wks |
| Zepbound 15 mg tirzepatide | SURMOUNT-1 (NEJM 2022) | −20.9% | 72 wks |
Why your result will differ
Averages hide a wide spread. In SURMOUNT-1, roughly a third of participants on the higher doses lost 25% or more — while others lost far less. Real-world loss is frequently lower than trials because of side effects, dose interruptions and stopping early. The strongest lever you control is consistency: reaching your dose, eating enough protein, and tracking so you can catch problems early.
It is not linear
Weight comes off fastest early and slows toward a plateau near the trial endpoint, with stalls and drops along the way. GLPMate's weight trend smooths the daily noise so a normal plateau doesn't read as failure.
Sources: STEP 1 (Wilding et al., NEJM 2021) — semaglutide 2.4 mg, −14.9% at week 68; SURMOUNT-1 (Jastreboff et al., NEJM 2022) — tirzepatide 5/10/15 mg, −15.0/−19.5/−20.9% at week 72. Educational illustration only — not medical advice, not a prediction, and not a promise of results. Talk to your prescriber about what to expect.
This tool applies published clinical-trial averages to a weight you enter. It is for general education only — not medical advice, not a diagnosis, not a prediction, and not a promise of any result. Individual outcomes vary widely, including no weight loss.
GLPMate is an independent tracking app and does not guarantee outcomes. Wegovy® and Zepbound® are trademarks of their respective owners (Novo Nordisk, Eli Lilly); GLPMate is not affiliated with or endorsed by them. Discuss expected results and any treatment change with your prescriber.
Sources
- STEP 1 and STEP 4 trials (semaglutide 2.4 mg) — published mean weight change
- SURMOUNT-1 and SURMOUNT-4 trials (tirzepatide) — published mean weight change
Last updated:
Weight-loss questions
How much weight do people lose on GLP-1 medications?
In the pivotal trials, adults averaged about 14.9% of body weight on semaglutide 2.4 mg (Wegovy, STEP 1) and 15–21% on tirzepatide 5–15 mg (Zepbound, SURMOUNT-1) over roughly 68–72 weeks, alongside diet and activity changes. These are averages — individual results ranged from little or no loss to more than 25%.
Is this a prediction of what I will lose?
No. This applies a published trial average to your weight to make the scale relatable. It is not a personal prediction and not a promise. Your result depends on dose, adherence, diet, activity, sleep, other medications and your own biology — and some people respond much more or much less than the average.
Why did trial participants lose more than some real-world users?
Trial participants reached and maintained the full dose with structured lifestyle support and close follow-up. Real-world results are often lower because of side effects, dose interruptions, cost-driven gaps or stopping early. Consistent tracking is one of the few things shown to help — which is exactly what GLPMate is for.
How fast does the weight come off?
Loss is fastest in the first several months and slows as you approach a plateau near the trial endpoint. It is rarely linear — most people see stalls and whooshes along the way. GLPMate charts your real trend so a normal plateau does not feel like failure.
What happens if I stop?
Trials (including STEP 4 and SURMOUNT-4) found that most people regain a substantial share of the lost weight after stopping, because the underlying appetite biology returns. GLP-1 therapy is generally long-term — discuss any change with your prescriber.
See your own trend.
Free weight tracking. iOS & Android.